Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 June 2023Next earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
INTS Latest News
SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, today announced that its Phase 3 trial has been selected for an oral podium presentation at the 2024 Connective Tissue Oncology Society (CTOS) on November 16, 2024.
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn. , Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces second quarter 2024 financial results and provides a corporate update.
Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets.
What type of business is Intensity Therapeutics Common stock?
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
What sector is Intensity Therapeutics Common stock in?
Intensity Therapeutics Common stock is in the Healthcare sector
What industry is Intensity Therapeutics Common stock in?
Intensity Therapeutics Common stock is in the Biotechnology industry
What country is Intensity Therapeutics Common stock from?
Intensity Therapeutics Common stock is headquartered in United States
When did Intensity Therapeutics Common stock go public?
Intensity Therapeutics Common stock initial public offering (IPO) was on 30 June 2023
What is Intensity Therapeutics Common stock website?
https://www.intensitytherapeutics.com
Is Intensity Therapeutics Common stock in the S&P 500?
No, Intensity Therapeutics Common stock is not included in the S&P 500 index
Is Intensity Therapeutics Common stock in the NASDAQ 100?
No, Intensity Therapeutics Common stock is not included in the NASDAQ 100 index
Is Intensity Therapeutics Common stock in the Dow Jones?
No, Intensity Therapeutics Common stock is not included in the Dow Jones index
When was Intensity Therapeutics Common stock the previous earnings report?
No data
When does Intensity Therapeutics Common stock earnings report?
The next expected earnings date for Intensity Therapeutics Common stock is 14 March 2025